Palbociclib has been shown to inhibit the growth of doxorubicin-resistant Ewing’s sarcoma patient-derived orthotopic xenografts in vivo, with a p16INK4A-deletion56. This evidence concerns the gene CDKN2A and Ewing sarcoma.